Xtalpi Holdings Limited · HKEX:2228
Xtalpi — H1 2025 Earnings Presentation
26 slides from Xtalpi's earnings presentation, Aug 27, 2025
Slide 1: XtalPi 1H25 Investor Presentation
2228.HK XtalPi 1H25 Investor Presentation 1
Slide 2: 1H25 Financial Highlights
1H25 Financial Highlights In 1H25, compared to 1H24, the Company’s revenue increased by 404%, achieving profitability for the first time on a half-year basis, with monthly average cash burn declining by 20%. RMB mn 1H25 YOY 1H24 Revenue 517 404 % 103 R&D Expenses 222 5 % 210 Turned Adjusted Net Prof
Slide 3: AI4S: Globally Recognized Force Transforming Drug R&D
22 28 . H K AI4S: Globally Recognized Force Transforming Drug R&D Platform-Powered Collaborative R&D in Innovation Ecosystem for AI + Robotics Forging Drug Discovery Novel Drugs & Therapeutics New Paradigm in R&D Landmark drug R&D agreement (USD XtalPi and Signet’s jointly developed XtalPi’s antibod
Slide 4: Drug Discovery Solutions
Drug Discovery Solutions World-leading AI and Robotics Drive New Growth for Our Business 4
Slide 5: AI + Robotics Platform Wins Global Recognition, Catalyzing New Growth Era
22 28 . H K AI + Robotics Platform Wins Global Recognition, Catalyzing New Growth Era Strategic Pipeline Collaboration With Rapid Antibody Commercialization, Biotech Pioneer Gregory Verdine From Tech Platform To Application Platform Tech Stack With a total deal size of US$5.99 billion, XtalPi sets a
Slide 6: Joint Pipeline Milestones Propel Industry Innovation
22 28 . H K Joint Pipeline Milestones Propel Industry Innovation Leading Biopharma Partner: 3 Joint Programs, 3 Key Milestones Joint Pipeline Update: Signet Therapeutics Nominated for Prix Galien Award (the ‘Nobel of Medicine’) – Best Biotechnology Product A chronic-disease collaboration launched in
Slide 7: Elevating AI to Forge a Drug Discovery Superintelligence
22 28 . H K Elevating AI to Forge a Drug Discovery Superintelligence Pfizer Partnership Deepens, Empowering AI-Driven Antibody Platform XtalFold® Better AI Drug Discovery Models Continues Iterative Upgrades We are building a next-generation foundational model for classical In 1H25, we launched the n
Slide 8: Launching Molecular Glue Platform, Developing New Business
22 28 . H K Launching Molecular Glue Platform, Developing New Business Native PPI Prior knowledge Diversity & Tissue VS, DEL, Compatibility -enrichment ASMS ... E3 E3 binder Core ✓ E3 binder-based ligase ID expansion D Compound Library design synthesis Protein of Interest (POI) POI-targeted M Undrug
Slide 9: Launching PepiX: Advanced Peptide & Protein Platform
22 28 . H K Launching PepiX : Advanced Peptide & Protein Platform Hits in 1–2 Months, Leads in 6 FIC Design for Months for Peptide Molecules Challenging Solid Tumor Lead Optimization Done IDP Drug Targets Blood Sugar- and in 2-3 Months Fat-Regulating Peptides AI-Driven De Novo Precision Computationa
Slide 10: Intelligent Robotics Solutions
2.2 Intelligent Robotics Solutions AI and Robotics Redefine the Future of Chemistry 10
Slide 11: AI and Robotics Reshape R&D with Vertical Artificial Superintelligence
22 28 . H K AI and Robotics Reshape R&D with Vertical Artificial Superintelligence High-Throughput Experiments, High-Quality Data, High-Intelligence Models Smart Smart Lab Robotic Software Vertical Structure Purification AI Models Prediction Laboratory / Analys is Reaction Reaction High-Quality Data
Slide 12: Future of Chemistry: Innovation Powered by Models and Data
22 28 . H K Future of Chemistry: Innovation Powered by Models and Data Chemical Reaction Data Fuels Smarter Models, Completed Acquisition of Better Predictions, and Next-Gen Chemistry Liverpool ChiroChem (LCC) Enhancing Database Capabilities Patent & Literature Mining and Autonomous Experiments Impr
Slide 13: AI Predictions Beat Human Experts, Leading Paradigm Shift
22 28 . H K AI Predictions Beat Human Experts, Leading Paradigm Shift Suzuki Coupling SNAr Reactions Sonogashira Coupling 137 Chemists vs AI 131 Chemists vs AI 177 Chemists vs AI AI Models 89% AI Models 81% AI Models 86% Positive Sample Prediction Results 1st Chemist Group 84% 1st Chemist Group 81%
Slide 14: Embodied AI Breakthrough for Robotic Lab Challenges
22 28 . H K Embodied AI Breakthrough for Robotic Lab Challenges Breakthroughs in Full-Process Lab Automation NeoDispenser Tackles Key Solid Dispensing Robots Boost Experiment Efficiency by Multiple Times Challenges in Labs Sample Advanced Visual Perception Intelligent Database Sample Feeding Synthes
Slide 15: AI Multi-Agents Reinvent R&D: Exploring Massive Chemical Space
22 28 . H K AI Multi-Agents Reinvent R&D: Exploring Massive Chemical Space with Autonomous Decision Systems Memory Workflow Analytical Report Agent Agent Agent Tools Planning Base LLM (QwQ, DeepSeek, Claude, etc) Agent MCP Tools AIDD and Chemistry Analytical Robotic Execution Chemical ETL AI Models
Slide 16: AI + Robotics Accelerates Discovery via Closed-Loop Wet/Dry Experimentation
22 28 . H K AI + Robotics Accelerates Discovery via Closed-Loop Wet/Dry Experimentation Small Molecule Drug Discovery Antibody Drug Discovery New Material Discovery Candidate Molecular Targets Molecules Structure Primary Structure XtalFold Validated Targets New Targets Sequence Structural Modeling L
Slide 17: Autonomous Lab Platform: Driving Cross-Industry Commercialization
22 28 . H K Autonomous Lab Platform: Driving Cross-Industry Commercialization to Empower Diverse Sectors Roche JW Pharma Liangzhu Lab 2025 Smart Storage for Fully Automated Drug All-in-One Smart Lab: Chemical Synthesis Synthesis Workflows Biomaterials Synthesis, Solutions Delivered Building Blocks C
Slide 18: 1H25 Financial Results
Xtal? 1H25 Financial Results
Slide 19: 1H25 Financial Highlights
1H25 Financial Highlights In 1H25, compared to 1H24, the Company’s revenue increased by 404%, achieving profitability for the first time on a half-year basis, with monthly average cash burn declining by 20%. RMB mn 1H25 YOY 1H24 Revenue 517 404 % 103 R&D Expenses 222 5 % 210 Turned Adjusted Net Prof
Slide 20: Strong Revenue Growth
Strong Revenue Growth Total Revenue 600 517 500 YOY 400 +404% 300 200 103 100 0 1H24 1H25 RMB mn 20 © 2025 XtalPi
Slide 21: Revenue Breakdown by Geography and Business Segment
Revenue Breakdown by Geography and Business Segment Revenue by Geographical Location (%) Revenue by Business Segment (%) Mainland China United States Others Drug Discovery Solutions Intelligent Robotics Solutions 1H24 1H25 1H24 1H25 16% 5% 41% 15% 15% 46% DoveTree 71% 39% 80% DoveTree 59% 71% 84% In
Slide 22: Operational Expenses
Operational Expenses R&D Expenses G&A Expenses RMB mn Employee Benefit Expenses Others RMB mn Employee Benefit Expenses Others 480,663 YOY 222 234 YOY 210 200 +5% -15% 1H24 1H25 1H24 1H25 ETR 205% 43% ETR 228% 39% S&M Expenses Cost of Revenue RMB mn Employee Benefit Expenses Others RMB mn Employee b
Slide 23: Achieved profitability for the first time on a half-year basis
Achieved profitability for the first time on a half-year basis Adjusted Net Profit/(loss) (Non-IFRS) RMB mn Adjusted Net Profit/(loss) turned 142 from a loss of RMB 251mn to a profit of RMB 142mn 1H24 1H25 (251) 23 © 2025 XtalPi
Slide 24: Cash Burn Rate and Cash Balance
Cash Burn Rate and Cash Balance Monthly Average Cash Burn Cash Balance RMB mn RMB mn Financial Assets at FVTPL（Current） Restricted Cash Term Deposit Cash and Cash Equivalents 5,308 YOY +70% YOY -20% 62 1,841 50 3,123 1,152 1,786 170 2,312 1,166 1H24 1H25 12/31/2024 6/30/2025 Average monthly cash bur
Slide 25: Q&A Thanks!
Q&A Thanks! 25 © 2025 XtalPi
Slide 26: 26
26